Join the Wegovy group to help and get support from people like you.
Wegovy News (Page 6)
GLP-1 RAs Reduce Risk for Clinically Important Kidney, CVD Outcomes
FRIDAY, Dec. 6, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes,...
Weight Loss Brings Americans Big Health Care Savings
THURSDAY, Dec. 5, 2024 – The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs' cost should be covered by Medicare, Medicaid and private...
Zepbound Bests Wegovy for Weight Loss in New Trial
WEDNESDAY, Dec. 4, 2024 – Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased...
New Weight-Loss Advance: A Gastric Balloon You Control to Feel Full or Not
TUESDAY, Dec. 3, 2024 – GLP-1 meds are all the rage for weight loss nowadays, but not everyone can safely take the drugs to shed pounds. Invasive weight-loss surgeries can often be a tough sell,...
American Heart Association, Nov. 16-18
The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, including cardiovascular specialists, surgeons, and n...
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
TUESDAY, Nov. 26, 2024 – The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy)...
Study Finds GLP-1 Meds, such as Ozempic, Wegovy, Can Also Help the Kidneys
TUESDAY, Nov. 26, 2024 – The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to...
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds, such as Wegovy, Zepbound
TUESDAY, Nov. 26, 2024 – The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and...
Stroke Guidelines Updated, With Focus on Women and GLP-1s
MONDAY, Nov. 25, 2024 – Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with a greater risk for stroke. They and other...
Taking a GLP-1 Medication? Here's Tips to Holiday Eating
SATURDAY, Nov. 23, 2024 – So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where...
Meds Like Ozempic Are Causing Folks to Waste More Food
FRIDAY, Nov. 22, 2024 – America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows. GLP-1s like Ozempic, Wegovy,...
AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
FRIDAY, Nov. 22, 2024 – More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the ...
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use Disorder
FRIDAY, Nov. 22, 2024 – Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD), according to a study published online Nov. 13 in JAMA...
Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption
THURSDAY, Nov. 21, 2024 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov....
More Than Half of U.S. Adults Could Be Candidates for Ozempic
TUESDAY, Nov. 19, 2024 – More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug semaglutide, a new analysis finds. Sold as Ozempic for...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction